diisopropylamine dichloroacetate (DIPA)

stimulates smooth muscle & strongly inhibits acetylcholinesterase activity

Also Known As:

DIPA; di-isopropylamine dichloroacetate; diisopropylammonium dichloroethanoate; dipromonium; diisopropylammonium dichloroacetate

Networked: 45 relevant articles (5 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Inorganic Chemicals: 9
- Nitrogen Compounds: 67
  - Ammonium Compounds: 1606
    - Quaternary Ammonium Compounds: 136
      - diisopropylamine dichloroacetate: 45
Organic Chemicals: 133
- Amines: 4871
  - Quaternary Ammonium Compounds: 136
    - diisopropylamine dichloroacetate: 45
- Onium Compounds
  - Quaternary Ammonium Compounds: 136
    - diisopropylamine dichloroacetate: 45

Experts

1.	Gigengack, Maj R: 2 articles (01/2020 - 01/2015)
2.	Lindauer, Ramón J L: 2 articles (01/2020 - 01/2015)
3.	van Meijel, Els P M: 2 articles (01/2020 - 01/2015)
4.	Yu, Decai: 2 articles (10/2016 - 10/2016)
5.	Indalao, Irene L: 2 articles (09/2016 - 01/2014)
6.	Kido, Hiroshi: 2 articles (09/2016 - 01/2014)
7.	Candotti, Cláudia T: 1 article (01/2020)
8.	Dutra, Vinícius H: 1 article (01/2020)
9.	Furlanetto, Tássia S: 1 article (01/2020)
10.	Hein, Irma M: 1 article (01/2020)

Related Diseases

1.	Human Influenza (Influenza) 01/01/2014 - "The present study tested the effects of diisopropylamine dichloroacetate (DADA), a new PDH kinase 4 (PDK4) inhibitor, in mice with severe influenza. " 01/01/2014 - "Diisopropylamine dichloroacetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza." 09/01/2016 - "These options are (i) restoration of glucose oxidation in mitochondria by diisopropylamine dichloroacetate, which inhibits infection-induced pyruvate dehydrogenase kinase 4 activity, and (ii) restoration of long-chain fatty acid oxidation in mitochondria by l-carnitine and bezafibrate, an agonist of peroxisome proliferation-activated receptors-β/δ, which transcriptionally upregulates carnitine palmitoyltransferase II. The latter is particularly effective in patients with influenza-associated encephalopathy who have thermolabile and short half-life compound variants of carnitine palmitoyltransferase II. "
2.	Non-alcoholic Fatty Liver Disease 02/01/2005 - "Diisopropylamine dichloroacetate could be used as a safe and effective drug in the treatment of nonalcoholic fatty liver diseases." 02/01/2005 - "[Diisopropylamine dichloroacetate in the treatment of nonalcoholic fatty liver disease: a multicenter random double-blind controlled trial]." 02/01/2005 - "To investigate the efficacy and safety of diisopropylamine dichloroacetate in the treatment of nonalcoholic fatty liver diseases (NAFLD). "
3.	Infections 01/01/1991 - "The DIPA appears to have potential application, especially as a 'dipstick' kit, for rapid and inexpensive laboratory diagnosis of bluetongue virus infection." 09/05/1960 - "[Influence of diisopropylammonium dichloroacetate (DIEDI) in experimental MHV-3 virus (mouse hepatitis virus) infection]." 09/01/2016 - "These options are (i) restoration of glucose oxidation in mitochondria by diisopropylamine dichloroacetate, which inhibits infection-induced pyruvate dehydrogenase kinase 4 activity, and (ii) restoration of long-chain fatty acid oxidation in mitochondria by l-carnitine and bezafibrate, an agonist of peroxisome proliferation-activated receptors-β/δ, which transcriptionally upregulates carnitine palmitoyltransferase II. The latter is particularly effective in patients with influenza-associated encephalopathy who have thermolabile and short half-life compound variants of carnitine palmitoyltransferase II. "
4.	Neoplasms (Cancer) 10/04/2016 - "Superior anti-tumor efficacy of diisopropylamine dichloroacetate compared with dichloroacetate in a subcutaneous transplantation breast tumor model." 01/01/2015 - "Herein, DCA and diisopropylamine dichloroacetate (DADA) were incorporated separately into polylactide (PLA) electrospun mats and applied to C26 tumor-bearing mice via in situ administration. "
5.	Infarction (Infarctions) 01/01/2017 - "DipA increased the number of CXCR4+ MNCs residing in the infarcted Eng+/- hearts (Eng+/- 73.17±12.67 vs. Eng+/- treated 157.00±11.61, P = 0.0003) and significantly reduced infarct size (Eng+/- 46.60±9.33% vs. Eng+/- treated 27.02±3.04%, P = 0.03). " 01/01/2012 - "Infarct thickness and cardiomyocyte number/infarct/section were significantly improved in MHC-cycD2 mice with G-CSF plus DipA treatment when compared with MHC-cycD2 transgene expression or G-CSF plus DipA treatment alone. "

Related Drugs and Biologics

1.	pyruvate dehydrogenase kinase 4
2.	Granulocyte Colony-Stimulating Factor (G-CSF)
3.	Glucose (Dextrose)
4.	Fatty Acids (Saturated Fatty Acids)
5.	Carnitine O-Palmitoyltransferase (Carnitine Palmitoyltransferase II)
6.	Carnitine (L-Carnitine)
7.	Bezafibrate
8.	Diclofenac (SR 38)
9.	Acetaminophen (Paracetamol)
10.	Pyruvate Dehydrogenase Acetyl-Transferring Kinase

Related Therapies and Procedures

1.	Transplantation